Evidence map›Paper›PMID 34930537›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2021

Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic: A qualitative analysis of interviews with cystic fibrosis care team members.

Aricca D Van Citters, Olivia Dieni, Peter Scalia, Christopher Dowd, Kathryn A Sabadosa, Jill D Fliege, Manu Jain, Robert W Miller, Clement L Ren

Open access · greenAbstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022
    Review
  13. Article
  14. The life rafts sailed; Now let's take stock and set the course ahead (Commentary).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021
    Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Aricca D Van CittersThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Williamson Translational Research Building, Level 5, One Medical Center Drive, Lebanon, NH, 03766, USA. Electronic address: Aricca.D.Van.Citters@Dartmouth.edu.
Olivia DieniCystic Fibrosis Foundation, 4550 Montgomery Avenue, Suite 1100N, Bethesda, MD 20814 USA.
Peter ScaliaThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Williamson Translational Research Building, Level 5, One Medical Center Drive, Lebanon, NH, 03766, USA.
Christopher DowdCystic Fibrosis Foundation, 4550 Montgomery Avenue, Suite 1100N, Bethesda, MD 20814 USA.
Kathryn A SabadosaCystic Fibrosis Foundation, 4550 Montgomery Avenue, Suite 1100N, Bethesda, MD 20814 USA.
Jill D FliegeAdult Cystic Fibrosis Nurse Practitioner / Program Coordinator; Pulmonary, Critical Care, Sleep and Allergy Medicine, 985990 Nebraska Medicine, Omaha, NE, 69198-5990, USA.
Manu JainDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Robert W MillerLehigh Valley Reilly Children's Hospital Cystic Fibrosis Center, 1210 Cedar Crest Blvd, Suite 2700, Allentown, PA, 18103, USA.
Clement L RenChildren's Hospital of Philadelphia, Division of Pulmonary and Sleep Medicine, Colket Translational Research Building, 3501 Civic Center Blvd, Philadelphia, PA, 19104, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Cystic Fibrosis Foundation · USDartmouth Institute for Health Policy and Clinical Practice · USChildren's Hospital of Philadelphia · USLehigh Valley Hospital · USNebraska Medical Center · USNorthwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic forced cystic fibrosis (CF) care programs to rapidly shift from in-person care delivery to telehealth. Our objective was to provide a qualitative exploration of facilitators and barriers to: 1) implementing high-quality telehealth and 2) navigating reimbursement for telehealth services.

methodsWe used data from the 2020 State of Care CF Program Survey (n=286 U.S. care programs) administered in August-September to identify two cohorts of programs, with variation in telehealth quality (n=12 programs) and reimbursement (n=8 programs). We conducted focus groups and semi-structured interviews with CF program directors and coordinators in December 2020, approximately 9 months from onset of the pandemic. We used the Consolidated Framework for Implementation Research to identify facilitators and barriers of implementation, and inductive thematic analysis to identify facilitators and barriers of reimbursement.

resultsFactors differentiating programs with greater and lower perceived telehealth quality included telehealth characteristics (perceived advantage over in-person care, cost, platform quality); external influences (needs and resources of those served by the CF program), characteristics of the CF program (compatibility with workflows, relative priority, available resources); characteristics of team members (individual stage of change), and processes for implementation (engaging patients and teams). Reimbursement barriers included documentation to optimize billing; reimbursement of multi-disciplinary team members, remote monitoring, and telephone-only telehealth; and lower volume of patients.

conclusionsA number of factors are associated with successful implementation and reimbursement of telehealth. Future efforts should provide guidance and incentives that support telehealth delivery and infrastructure, share best practices across CF programs, and remove barriers.

Indexed as

Communication BarriersCOVID-19Cystic FibrosisHealth Services AccessibilityPatient ParticipationTelemedicineAdultAttitude of Health PersonnelChildDisease Transmission, InfectiousHumansNeeds AssessmentQualitative ResearchQuality ImprovementReimbursement MechanismsSARS-CoV-2BarriersCystic fibrosisFacilitatorsImplementationTelehealth

Identifiers

PMID34930537
PMCPMC8683122
OpenAlexW4200256644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.